A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
ALX Oncology Inc.
Pfizer
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
Pheon Therapeutics
Eli Lilly and Company
Travera Inc
Revolution Medicines, Inc.
Seagen Inc.
Turning Point Therapeutics, Inc.
Alterome Therapeutics, Inc.
Orano Med LLC
RasCal Therapeutics, Inc.
Pfizer
Xencor, Inc.
A2 Biotherapeutics Inc.
Mirati Therapeutics Inc.
Arvinas Inc.
MBrace Therapeutics
New Phase Ltd.
Revolution Medicines, Inc.
Pheon Therapeutics
EXoPERT
Eli Lilly and Company
Novartis
Var2 Pharmaceuticals
Takeda
NantCell, Inc.
AstraZeneca
Revolution Medicines, Inc.
Tempus AI
Massive Bio, Inc.
Chongqing Precision Biotech Co., Ltd
HUYABIO International, LLC.
HUYABIO International, LLC.
A2 Biotherapeutics Inc.
Elicio Therapeutics
Revolution Medicines, Inc.
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
Alaunos Therapeutics
Novita Pharmaceuticals, Inc.
Gene Solutions
Apollomics Inc.
ModeX Therapeutics, An OPKO Health Company
Hoffmann-La Roche
Compugen Ltd
Tempus AI
Black Diamond Therapeutics, Inc.